-
Mashup Score: 1Final Overall Survival Analysis in HRR-Deficient Cohort in TALAPRO-2: Addition of Talazoparib to Enzalutamide in Metastatic CRPC - 4 hour(s) ago
As reported in The Lancet by Fizazi et al, the final overall survival analysis in the homologous recombination repair (HRR)–deficient metastatic castration-resistant prostate cancer (CRPC) cohort of t…
Source: ascopost.comCategories: General Medicine NewsTweet
-
Mashup Score: 1Addition of Talazoparib to Enzalutamide in Metastatic CRPC in Genetically Unselected Cohort - 7 hour(s) ago
As reported in The Lancet by Agarwal et al, the final overall survival analysis of the phase III TALAPRO-2 trial showed that the addition of talazoparib to enzalutamide resulted in a significant benef…
Source: ascopost.comCategories: General Medicine NewsTweet-
Talazoparib + enzalutamide in metastatic CRPC (HRR-unselected patients): • OS: 45.8 vs 37.0 mos (HR 0.80; P = .016) • rPFS: 33.1 vs 19.5 mos (HR 0.67; P < .0001) @neerajaiims 🔗 https://t.co/JSpsbZiiqG #ProstateCancer #OncologyResearch https://t.co/NeLcmSMLh3
-
-
Mashup Score: 3
Results from a retrospective study showed that the BCMA-directed CD3 T-cell engager produced clinically meaningful responses in heavily pretreated patients with relapsed or refractory multiple myeloma…
Source: ascopost.comCategories: General Medicine News, Partners & KOLsTweet-
RT @AlGarfall: https://t.co/hSxDt3C0KV
-
-
Mashup Score: 4Esophageal Adenocarcinoma Recurrence Patterns With Perioperative Chemotherapy vs Preoperative Chemoradiotherapy - 1 day(s) ago
In an analysis from the German phase III ESOPEC trial reported in the Journal of Clinical Oncology, Hoeppner et al found that perioperative chemotherapy reduced distant recurrence vs preoperative chem…
Source: ascopost.comCategories: General Medicine NewsTweet-
Perioperative FLOT chemo reduced distant recurrence and improved survival vs preoperative CROSS chemoradiotherapy in nonmetastatic esophageal adenocarcinoma📊 Phase III ESOPEC trial, 438 patients 👨🔬 Jens Hoeppner, MD 🔗 https://t.co/aKldNHjgcx #GastroOncology #ClinicalEvidence https://t.co/wNN2oEgBIV
-
-
Mashup Score: 2ACS Study Finds Firefighters Face Increased Cancer Risk and Mortality, Especially for Skin and Kidney Cancers - 1 day(s) ago
Being a firefighter increased the mortality risk for most cancers, especially for skin and kidney cancers, according to the results from a large prospective study by the American Cancer Society. Incre…
Source: ascopost.comCategories: General Medicine NewsTweet-
🧯Firefighters face heightened mortality risk from skin and kidney cancers, with longer service also linked to prostate, colorectal, and lung cancer mortality. Study from @ACSNews, led by Lauren R. Teras, PhD https://t.co/ZHSIIVNruY #OccupationalHealth #CancerRisk https://t.co/U5UoH9ww1L
-
-
Mashup Score: 6Three in Five Liver Cancer Cases May Be Due to Preventable Risk Factors, The Lancet Commission Finds - 2 day(s) ago
“Liver cancer is a growing health issue around the world. It is one of the most challenging cancers to treat, with 5-year survival rates ranging from approximately 5% to 30%. We risk seeing close to a…
Source: ascopost.comCategories: General Medicine NewsTweet-
🧬 Over 60% of global liver cancer cases may be preventable by targeting viral hepatitis, alcohol use, and MASLD, according to @TheLancet Commission. 👨⚕️ Lead contributors include @SeragHashem et al. 🔗 Learn more: https://t.co/hua1dq6dhr #LiverCancerPrevention #GlobalHealth https://t.co/F2gntYzCAh
-
-
Mashup Score: 17
“[This milestone underscores] the long-term potential of dual immunotherapy in unresectable HCC. The findings of this study offer a new horizon of hope for patients and health-care providers alike, re…
Source: ascopost.comCategories: General Medicine NewsTweet-
STRIDE (single tremelimumab, regular interval durvalumab) achieved a 5-year OS rate of 19.6% in unresectable HCC vs 9.4% with sorafenib in the phase III HIMALAYA trial Investigators included @LorenzaRimassa and @GABOUALFA 🔗 https://t.co/rLWtCGWb1A #Immunotherapy https://t.co/w2ZPIbfAYx
-
-
Mashup Score: 4
Combining the CD79b-directed antibody-drug conjugate polatuzumab vedotin-piiq with rituximab, gemcitabine, and oxaliplatin (R-GemOx) significantly improved survival outcomes in patients with transplan…
Source: ascopost.comCategories: General Medicine NewsTweet-
In the phase III POLARGO trial, @DrMatasar, reported that adding polatuzumab vedotin to R-GemOx reduced mortality by ~40% in relapsed/refractory DLBCL. 📊 270 patients ⏱️ Median OS: 19.5 vs 12.5 months (HR 0.60) 🔗 https://t.co/D9bgzpoFND #DLBCL #PolatuzumabVedotin https://t.co/ZjhbrEAytN
-
-
Mashup Score: 20Evidence of Potential Cure With Single CAR T-Cell Infusion for Some Patients With Multiple Myeloma - 3 day(s) ago
In long-term results from the CARTITUDE-1 trial, investigators had found that the autologous cellular immunotherapy ciltacabtagene autoleucel was potentially curative for one-third of patients with he…
Source: ascopost.comCategories: General Medicine NewsTweet-
CARTITUDE‑1: Single #CARTCellTherapy infusion shows potential for cure in relapsed/refractory #MultipleMyeloma 📊 5-year PFS in 33% of patients; MRD & PET-negative in subset 🗞️ July cover story of The ASCO Post 👨⚕️ Peter M. Voorhees, MD 🔗 https://t.co/peIAjnapzm https://t.co/DprAAuT3db
-
-
Mashup Score: 2
A large prospective cohort study found that, after adjusting for familial and other cancer-related factors, interstitial lung disease was associated with an increased risk of developing most histologi…
Source: ascopost.comCategories: General Medicine NewsTweet-
Interstitial lung disease linked to ≥2x the risk for lung cancer across subtypes, even after adjusting for genetic and familial factors. 📊 5.4M+ individuals, sibling-controlled 👨⚕️ Investigators: Weimin Ye, MD; Mingqiang Kang, MD 🔗 https://t.co/rIesFfgh8Q #ILD #LungCancer
-
TALAPRO‑2: talazoparib + enzalutamide in HRR-deficient mCRPC 🔹OS: 45.1 vs 31.1 mo (HR 0.62; P = .0005) 🔹rPFS: 30.7 vs 12.3 mo (HR 0.47; P < .0001) 🔹Grade ≥3 TRAEs: 59% vs 14% 🧑⚕️Karim Fizazi, MD 🔗 https://t.co/KA4YiO3Ko4 #ProstateCancer #OncologyResearch https://t.co/YRxHBCYjQS